Gesynta Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.gesynta.se
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Gesynta Pharma AB
- Target Recruit Count
- 94
- Registration Number
- NCT04744207
- Locations
- 🇬🇧
Investigator Site, London, United Kingdom
🇬🇧Investigator site, Manchester, United Kingdom
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
Phase 1
Completed
- Conditions
- Pharmacokinetic
- Interventions
- Drug: Formulation A GS-248Drug: Formulation B GS-248
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Gesynta Pharma AB
- Target Recruit Count
- 14
- Registration Number
- NCT04617509
- Locations
- 🇸🇪
Clinical Trial Consultants AB, Uppsala, Sweden
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Gesynta Pharma AB
- Target Recruit Count
- 72
- Registration Number
- NCT04036227
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath